Drugs / [11C]savolitinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06348355 | Apr → Jun 2024 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [11C]savolitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06348355 ↗ |
| Route | Intravenous | “Single microdose (≤ 10 μg) of \[11C\]savolitinib administered as an IV bolus at the start of PET imaging” NCT06348355 ↗ |